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IntrOductIOn
Acinetobacter spp. is Gram-negative coccobacilli with wide 
distribution in environmental sources such as soil and water. They 
are also common organisms found in the hospital environment 
[1]. Recent molecular studies have shown 31 distinct species with 
valid names among the genus Acinetobacter. Besides, the genus 
comprises a number of taxa including species with published 
names [2,3]. Of these, A. calcoaceticus, A. baumannii, A. pilli, and 
A. nosocomialis (genomic species 1, 2, 3 and 13TU, respectively) 
are genetically and phenotypically very similar [4]. 
During the last 20 years, Acinetobacter species have emerged 
as opportunistic and important nosocomial pathogens that are 
associated with hospital acquired infections [5]. A. baumannii is the 
most important species is responsible for a signiﬁcant proportion 
of nosocomial infections, including urinary tract infections, 
endocarditis, surgical-site infections, meningitis, septicemia, and 
ventilator-associated pneumonia among patients in intensive care 
units [6]. A. baumannii has more recently become a cause for major 
concern in clinical practice due to its high level of antimicrobial 
resistance. In particular, the worldwide emergence of the resistance 
to carbapenems [7], which have been accounted as the most 
effective antimicrobial agents for the treatment of infections caused 
by multidrug resistant (MDR), is reported increasingly [8]. Outbreaks 
of carbapenem-resistant A. baumannii were recently reported from 
Pakistan, Korea and China [9-11]. Due to growing importance of 
Acinetobacter species in hospital infections and particularly those 
with multidrug resistance capacity, the precise identiﬁcation of the 
species is important to elucidate the ecology, epidemiology, and 
pathology of these species. Conventional phenotypic tests are 
 
proved to be unable to identify the Acinetobacter isolates to the 
species level [4]. However, in recent years, species identiﬁcation has 
been made possible by using the developed molecular techniques 
[12]. These methods include the currently identiﬁcation methods 
based on 16S rRNA and RNA polymerase B subunit (rpoB) 
genes sequences, for the description of Acinetobacter species. 
Both methods have been reported to be useful for molecular 
characterization of bacteria including Acinetobacters [13,14]. 
The objectives of the present study were to apply the molecular 
methods for the species identiﬁcation of the Acinetobacter spp. 




A total of 197 non-duplicate isolates from a wide range of clinical 
samples were collected from Golestan and Imam Khomeini teaching 
Hospitals in Ahvaz and Sina Hospital in Tehran from November 
2011 to January 2013. Clinical sources of the isolates were blood, 
endotracheal, urine, wound, sputum, exudates, percutaneous 
endoscopic gastrostomy (PEG), pleural fluid, cerebrospinal fluid 
(CSF), and soft tissue, though the majority of strains were isolated 
from endotracheal tube and blood. The isolates were kept in 
Trypticase Soy Broth (Merck, Germany) containing 20% glycerol at 
-80°C until use. Conventional phenotypic tests including growth on 
MacConkey agar (Merck, Germany), sugar fermentation, motility, 
catalase, oxidase, and other standard recommended tests were 
used to identify the genus of the isolates [15]. 
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Background: Acinetobacter spp. is a diverse group of Gram-
negative bacteria which are ubiquitous in soil and water, and 
an important cause of nosocomial infections. The purpose of 
this study was to identify a collection of Acinetobacter spp. 
clinical isolates accurately and to investigate their antibiotic 
susceptibility patterns.
Materials and Methods: A total of 197 non-duplicate 
clinical isolates of Acinetobacter spp. isolates identified using 
conventional biochemical tests. The molecular technique 
of PCR-RFLP and sequence analysis of rpoB and 16S rRNA 
genes was applied for species identification. Antimicrobial 
susceptibility test was performed with a disk diffusion assay.
results: Based on 16S rRNA and rpoB genes analysis 
separately, most of clinical isolates can be identified with high 
bootstrap values. However, the identity of the isolate 555T was 
uncertain due to high similarity of A. grimontii and A. junii. 
Identification by concatenation of 16S rRNA and rpoB confirmed 
the identity of clinical isolates of Acenitobacer to species level 
confidently. Accordingly, the isolate 555T assigned as A. grimontii 
due to 100% similarity to A. grimontii. Moreover, this isolate 
showed 98.64% to A. junii. Besides, the identity of the isolates 
218T and 364T was confirmed as Genomic species 3 and A. 
calcoaceticus respectively. So, the majority of Acinetobacter 
spp. isolates, were identified as: A. baumannii (131 isolates, 
66%), A. calcoaceticus (9 isolates, 4.5%), and A. genomosp 16 
(8 isolates, 4%). The rest of identified species showed the lower 
frequencies. In susceptibility test, 105 isolates (53%), presented 
high antibiotic resistance of 90% to ceftriaxone, piperacillin, 
piperacillin tazobactam, amikacin, and 81% to ciprofloxacin.
conclusion: Sequence analysis of the 16S rRNA and rpoB spacer 
simultaneously was able to do identification of Acinetobacter 
spp. to species level. A.baumannii was identified as the most 
prevalent species with high antibiotic resistance. Other species 
showed lower frequencies ranged from 4 to 9 strains.
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Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by agar disc 
diffusion method according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines [16]. The following antimicrobial agents 
were tested: ciprofloxacin (30µg), piperacillin (100µg), gentamycin 
(10µg), amikacin (30µg), trimethoprim sulfamethoxazole (25µg), 
meropenem (10µg), piperacillin tazobactam (100/10µg), ceftazidime 
(30µg), ceftriaxone (30µg), polymyxinB (20µg) and tetracycline (30µg) 
{MAST Co., UK}. A. baumannii ATCC 16906 was used as control 
strain. Determination of MDR and extensively drug resistance (XDR) 
was based on the CLSI criteria reported elsewhere [17]. 
Molecular identification
DnA extraction
All the isolates were grown on Muller Hinton Agar (Merck, Germany) 
and were incubated for 48 hours at 37°C under aerobic conditions 
and the bacterial colonies were then used for DNA extraction. The 
boiling method described by Higgins et al., [18], was used to extract 
the DNA from the bacterial colonies. 
Fingerprinting of the 16S rrnA gene by PCr-rFlP analysis for 
strain clustering
Ampliﬁcation of the 16S rRNA gene (1500 bp) was performed by 
using universal primers 27F (5’-AGAGTTTGATYMTGGCTCAG-3’) 
and 1525R (5’-AGAAAGGAGGTGATCCAGCC-3’) and PCR 
protocol as described elsewhere [14,19]. The PCR products were 
electrophoresed on a 2% agarose gel containing 0.5 µg/ml ethidium 
bromide (Qiagen, USA) to determine the size of the product. Both 
negative and reagent controls were included in each PCR run. The 
product was photographed by using the gel documentation system 
(UV Tech, UK). All PCR products were then digested by Hae III and 
Tag I restriction enzymes (Fermentas, Canada). Enzymatic digestion 
of the PCR products was performed according to the manufacturer's 
instructions. In brief, 10 µl of the amplicon was treated separately 
with 2 units of TaqI or Hae III enzymes plus 10 µl corresponding 
buffer and were overnight incubated at 37oC. The digested reactions 
were then placed at 65°C for 30 minutes to avoid further enzymatic 
digestion. Ten microliters of digestion products were separated by 
electrophoresis on a 3% agarose gel containing 0.5 µg/ml ethidium 
bromides. A. baumannii ATCC16906 was used as a positive 
control. Restriction patterns were analysed visually comparing with 
a 1000 bp DNA size marker, to group the patterns according to a 
similarity coefﬁcient using the UPGMA method, allowing a 5% level 
of discrimination between the bands. 
nucleotide sequence determination of rpoB and 16S rDnA 
genes and phylogenetic analysis
One isolate from each cluster was selected randomly for further 
identiﬁcation by sequencing of 16S rDNA and rpoB. The PCR 
products were sequenced using 27F, 1525R and 907R (5’-
CCGTCAATTCMTTTRAGTTT-3’) with an ABI 3100 genetic analyser. 
To determine the sequencing of PCR products, commercial kit of 
Dye Terminator Cycle Sequencing Genmeo Lab TM (Biometra Co., 
Germany), according to the manufacturer’s instructions was used. 
Zone 1 of the rpoB gene (350bp) was ampliﬁed from randomly 
selected isolate of each group using the primers Ac696F 
(5’-TAYCGYAAAGAYTTGAAAGAAG-3’) and Ac1093R (5’-
CMACACCYTTGTTMCCRTGA-3’) as described elsewhere [14]. 
The PCR products were sequenced using Ac696F and Ac1093R.
Multiple alignments, sequence similarities of the 16S rDNA and rpoB 
gene were determined with all existing sequences of type strain of 
Acinetobacter retrieved from GenBankTM database using the jPhydit 
program [20]. 
The phylogenetic relationship between sequences of the 16S rDNA 
and rpoB genes was estimated by the neighbor-joining method. 
After the construction of phylogenetic trees, bootstrap replicates 
were performed to estimate their node reliabilities using the MEGA 
4 program. 
The GenBank accession numbers for the sequences of the 16S 
rRNA and rpoB genes of the representative isolates are KM281495-
KM281506 and KM668180-KM668191 respectively.
rEsuLts
The clinical isolates of Acinetobacter belonged to 130 male (66%) 
and 67 female (34%) patients with an age range of 2 to 84 years. 
The majority of the isolates were from endotracheal tubes (95 
isolates, 48.2%), followed by ulcer discharge (26 isolates, 13.2%) 
and urine (27 isolates,13.7%).  The results from susceptibility testing 
showed that 159 (81%) Acinetobacter isolates were MDR and 26 
(13%) were XDR. The rate of antibiotic susceptibility was only 6% 
(12 isolates). The highest antibiotic resistance among Acinetobacter 
isolates were equally (96%) seen against ceftriaxone, piperacillin and 
piperacillin tazobactam, while polymyxin B was the most sensitive 
antibiotic (49.2%) in present study [Table/Fig-1].
The isolates showed several RFLP patterns which were grouped 
into 13 clusters designated from A to M. The majority of isolates 
were classiﬁed in A (131 isolates, 66.5%) [Table/Fig-2,3]. Most of 
clinical isolates can be conﬁdently identiﬁed with high bootstrap 
values using 16S rRNA gene sequencing. However based on 16S 
rRNA gene, the identity of the isolate 555T was uncertain due to 
high similarity of A. grimontii and A. junii. Similarly on the basis of 
16S rRNA gene, the isolates 218T and 364T were unidentiﬁable 
due to identical 16S rRNA sequence of genomic species (Gen.sp.) 
3 and A. calcoaceticus.
Sequence analysis of zone 1 of the rpoB gene for representative 
isolates from each cluster in RFLP grouping, identiﬁed most of the 
isolates to species level with high similarity. Based on rpoB gene, 
clinical isolate 555T showed 100% and 99% similarity to those of 
A. grimontii. and Gen. sp. 5 (A. junii) respectively. Based on rpoB 
gene, the isolates 218T and 364T were identiﬁable to species level 
conﬁdently of Gen. sp.3 A. calcoaceticus.
Identiﬁcation by concatenation of 16S rRNA and rpoB conﬁrmed 
the identity of clinical isolates of Acenitobacer to species level. 
Accordingly, the isolate 555T assigned as A. grimontii due to 100% 
similarity to A. grimontii [Table/Fig-2]. Moreover, this isolate showed 
98.64% (24 nucleotide mismathes) to A. junii. On the other hand, 
the identity of the isolates 218T and 364T was conﬁrmed as Gen. 
sp. 3 and A. calcoaceticus respectively [Table/Fig-4].
dIscussIOn
Acinetobacter spp. and mainly A. baumannii are associated with 
hospital outbreaks worldwide. These organisms are particularly 
problematic due to the large number of MDR strains that have 
become endemic in hospital settings which is a growing concern in 
many countries [21,22]. 
In the present study, A. baumannii was the most prevalent (66.5%) 
Acinetobacter species. Several studies have investigated the 
distribution of Acinetobacters in clinical specimens at the species 
level, and considerable differences in outcome have been reported. 
In a recent report by Lee et al., [23], about 80% of their Acinetobacter 
isolates were identiﬁed as A. baumannii, which was higher than our 
ﬁndings. This rate was much lower in the study of Karah et al., [12], 
as 24% and in the study of Boo et al., [24], as 22%. In the latter 
study, A. pittii was the most frequent species found, representing 
39% of their 114 isolates, whereas only 4 isolates in our study 
were identiﬁed as A. pittii, which the difference is considerable. This 
inconsistency may be explained either by the use of different interval 
surveillance cultures in their study or by the use of different methods 
for species identiﬁcation. However, whether these differences are 
due to geographic, methodological, or epidemiological differences 
between the studies is hard to say.
Our ﬁnding represented extremely high rate of MDR as 81% and 
lower rate of XDR as 13%. This was in line with a report by Joshi et 
al., with more than 75% MDR among their Acinetobacter isolates 
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[25]. Similarly a recent report from Pakistan represented higher 
multidrug resistance as 96.6% among their tested Acinetobacter 
strains [9]. Although there are some discordant reports with much 
lower rate of MDR as 5.6% and 7.7% respectively [26,27]. A likely 
explanation for the relatively low level of resistant Acinetobacter 
isolates in latter studies is probably the restricted use of antibiotics, 
which is in line with the practice regarding antimicrobial therapy in 
their countries, the strict isolation of patients with MDR isolates, and 
the immediate beginning of infection control measures when several 
patients are infected with the same strain.
Identiﬁcation to species level within the genus Acinetobacter is 
often problematic. Currently Acinetobacter species are deﬁned on 
number (Acinetobacter) isolates AMK CiP Ctz PMb MrP tMP-
SMX
CtX tzP PiP gen tCn MDr 
Status
57,136,113, 82           A.pittii S S I S S S I S I R S _
25,34,85,148            A.schindleri R R R S I R R R R R R XDR
AC99,2, 17,28 A.calcoaceticus S S S S R S R R R S S MDR
70,104,117,129 A.gen.sp. 16 R R R S R R R R R R I MDR
79,96,108,120 A.gen.sp. 9 R R R I R R R R R R I MDR
35,12,20,22,23,52,48,49 A.baumanii S S S S S S S S S S S _
60,65,95*161,66, 67,69,80,81 A.baumanii R R R S R R R R R R S XDR
51,55,58,36,37,54,61,62,46,162 A.baumanii R R R S R I R R R S I MDR
41, 45 ,50,9 ,14,15, 32,123,71  A.baumanii R R R R R R R R R R I MDR
26,29,40,53,64,76,89,101,125,152,4,18,6,59,24
,72,73,74,84,86,98,19,30,31,42 ,44







A.baumanii R R R R R I R R R R R MDR
313,470,79,415,553 527,27,475,545        A.baumanii R R R S R R R R R S R XDR
99,384,169,339,379          A.lwoffii R R I I R R R R R I R MDR
36,505,25,262 A.ursingii R S S S R R R R R R R MDR
20,476,420,546,550,670 A.johnsonii R R R S R I R R R R I MDR
227,106,233,406 A.parvus S R R S I R R R R I I MDR
218,49,56,121 A.gen.sp. 3 R R R R R R R R R R R XDR
544,59,502,409 A.gen.sp.16 S R R S I R R R R R I MDR
544,59,502,409 A.genompsp.16 S R R S I R R R R R I MDR
555,67,127,552 A.girmontii S R R I R I R R R S I MDR
364,255,259,319,336  A.calcoaceticus S I S S R I R R R I I MDR
383,26,41,76,469,509 A.gen.sp. 13 TU S R R R I R R R R S I MDR
[table/Fig-1]: Antibiotic susceptibility patterns of clinical isolates of Acinetobacter spp. 
Isolates were designated susceptible (S), intermediate (I), or resistant (R) according to antibiotic breakpoint guidelines of the CLSI  for Acinetobacter  spp. Antibiotic abbreviations: 
AMK: Amikacin, CIP: Ciprofloxacin, CTZ: Ceftazidime , PMB: Polymyxin B , MRP: Meropenem , TMP-SMX: Trimethoprim Sulfamethoxaxole,  CTX: Ceftriaxone , TZP: Piperacillin 
tazobactam , PIP: Piperacillin, GEN: gentamicin, TCN: Tetracycline.
[table/Fig-2]: Restriction patterns and clustering of clinical isolates of  Acinetobacter 
spp. by 16S rRNA RFLP.
number 
of isolates 
Hae iii Tag i rFlP type
131 100/170/220/250/300/400 100/220/300/320/480 A
4 100/220/250/350/400 220/350/370/470 B
4 50/120/250/300/400 200/310/400/600 C
8 100/170/220/250/300/400 120/250/320/480/600 D
4 100/170/220/250/300/400 70/180/420/610 E
9 100/170/220/250/300/400 70/180/320/610 F
10 70/180/230/400 90/160/400/520 G
5 80/170/200/250/300/390 220/300/320/450 H
4 90/170/220/250/470 100/290/300/320/550 I
6 100/220/250/300/550 50/280/300/320/450 J
4 170/210/250/400/630 90/230/300/320/400 K
4 170/320/450/510 80/120/300/320/390 L
4 170/210/250/420/680 90/210/300/320/400 M
[table/Fig-3a,b ]: Enzymatic digestion of  16S rRNA  gene PCR products with (a) 
Hae III; (b) Tag I restriction enzymes with subsequent separation of the digested 
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the basis of a battery of phenotypic tests and several genotypic 
methods [12]. Among the latter, 16S rRNA gene sequencing is one 
of the most commonly used for bacterial identiﬁcation [22]. However, 
the main limitation of 16S rRNA gene sequencing is due to being 
too conserved and is not polymorphic enough to differentiate all 
Acinetobacter spp. [28]. Other protein-encoding genes, including 
recA, rpoB, gyrB, have recently been used for the identiﬁcation of 
Acinetobacter isolates. Among them, rpoB gene due to variability 
in its size in different bacterial species, comprises priority for 
typing subspecies [12,29,30]. In the current study, the isolates 
were subjected to phenotypic and sequence based identiﬁcation 
to access the species spectrum of clinically important species of 
Acinetobacter.
The obtained results revealed that although the 16S rRNA is able 
to identify most isolates to species level, however as previously 
stated, because of low polymorphisms, it is not suitable genetic 
marker for identiﬁcation. The isolates 555T, 218T and 364T were 
poorly discriminated by the 16S rRNA gene sequence. Identity of 
isolate 555T was unclear by rpoB sequencing as well. Although, 
simultaneous application of both 16S rRNA and rpoB techniques, 
was able to identify the randomly selected isolates to species level. 
Our ﬁnding showed 98.64% similarity between A. grimontii and A. 
junii. These are the species which previously were shown to be 
identical based on the complete rpoB gene sequences [18]. Other 
pair species showed less similarities by combination techniques 
and could not assigned as the identical species in pair wise 
comparisons. 
According to the reports by other investigators, the discriminating 
power of 16S rRNA gene sequencing is known to be lower than that 
of rpoB gene sequencing [14,31]. Although the rpoB signiﬁcantly 
improved the resolution of species identiﬁcation and complemented 
the phylogeny of genus Acinetobacter based on 16S rRNA gene 
sequences, in our study, using the concatenated sequence analysis 
of 16S rRNA and rpoB of representative isolate of each RFLP 
pattern, facilitated molecular identiﬁcation for clinical isolates [Table/
Fig-4]. These data clearly showed that identiﬁcation based on single 
technique is not suitable for reliable identiﬁcation and combination 
of 16S rRNA and rpoB genes analysis markedly improved the ability 
of the sequence based identiﬁcation.
cOncLusIOn
Sequence analysis of the 16S rRNA and rpoB spacer simultaneously 
was able to do identiﬁcation of Acinetobacter spp. to species level. 
A. baumannii was identiﬁed as the most prevalent species with 
high antibiotic resistance. Other species showed lower frequencies 
ranged from 4 to 9 strains. 
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